TRONTIER study: Evaluating trontinemab for early Alzheimer's disease treatment.
The TRONTIER study is a phase 3 clinical trial conducted by Roche to test a new drug, trontinemab, in people with mild cognitive impairment (MCI) to mild dementia due to Alzheimer's disease. This treatment is experimental and not yet FDA-approved.
Eligibility Criteria
Study goal and designPhase 3 study targeting amyloid-beta in early Alzheimer's
The TRONTIER study is a Phase 3 clinical trial conducted by Roche, testing a new drug called Trontinemab in people with mild cognitive impairment (MCI) to mild dementia due to Alzheimer's disease. The study checks if it's safe and if it can help by removing harmful amyloid-beta protein from the brain using a special technology to get the drug into the brain more effectively.
Study-related care and supportComprehensive medical oversight and support
While contributing to research, participants receive:
- The possibility to receive trontinemab investigational study medication
- Regular brain scans and memory assessments
- Study visits with qualified medical professionals
All medical and travel costs related to the study are covered.
Volunteer journeyA structured research experience
1 - Express your interest: Answer a questionnaire to check preliminary criteria.
2 - Meet the study team: Complete a detailed brain and memory evaluation.
3 - Begin treatment (or placebo): Receive trontinemab or placebo by intravenous infusion. Participation duration is 72 weeks.
4 - Continue the study : Be monitored during follow-up visits, and get health check-ups to observe any changes in cognition.
Join the TRONTIER study
Contribute to progress, support research, help others, and care for your health.
Participate in the study